Cargando…

Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population

BACKGROUND: The tumor suppressor TP53 and its negative regulator MDM2 play crucial roles in carcinogenesis. Previous case-control studies also revealed TP53 72Arg>Pro and MDM2 309T>G polymorphisms contribute to the risk of common cancers. However, the relationship between these two functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Mang, Zhang, Lei, Zhu, Xinhua, Huang, Jun, Jiang, Huifen, Hu, Sunhong, Liu, Yuehui
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861659/ https://www.ncbi.nlm.nih.gov/pubmed/20398418 http://dx.doi.org/10.1186/1471-2407-10-147

Ejemplares similares

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
por: Di Vuolo, Valeria, et al.
Publicado: (2011)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

TP53 and MDM2 polymorphisms and the risk of endometrial cancer in postmenopausal women
por: Zając, Agnieszka, et al.
Publicado: (2014)

Investigation of ATM, TP53 and MDM2 polymorphisms and their association with outcome of radiotherapy for prostate cancer
por: Cintra, Hellen S, et al.
Publicado: (2013)

Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms
por: Cabezas, Maria, et al.
Publicado: (2019)

MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
por: Foulkes, W. D., et al.
Publicado: (1995)

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
por: Hori, Yasuki, et al.
Publicado: (2015)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Individual and combined effect of TP53, MDM2, MDM4, MTHFR, CCR5, and CASP8 gene polymorphisms in lung cancer
por: Stumbryte, Ausra, et al.
Publicado: (2017)

Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women
por: Floris, Matteo, et al.
Publicado: (2022)

Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer
por: YONEDA, TOMOKO, et al.
Publicado: (2013)

Correction: Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma
Publicado: (2015)

TP53 and MDM2 Gene Polymorphisms, Gene-Gene Interaction, and Hepatocellular Carcinoma Risk: Evidence from an Updated Meta-Analysis
por: Peng, Qiliu, et al.
Publicado: (2013)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma
por: Ognjanovic, Simona, et al.
Publicado: (2012)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Combined Effects of Genetic Variants of the PTEN, AKT1, MDM2 and p53 Genes on the Risk of Nasopharyngeal Carcinoma
por: Zhang, Xiaoai, et al.
Publicado: (2014)

ATRT-08. TARGETING THE TP53-MDM2 ENHANCES RADIATION SENSITIVITY IN ATRT
por: Alimova, Irina, et al.
Publicado: (2021)

Uncommon non-oncogenic HPV genotypes, TP53 and MDM2 genes polymorphisms in HIV-infected women in Southern Brazil
por: Entiauspe, Ludmila Gonçalves, et al.
Publicado: (2014)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

Period2 downregulation inhibits glioma cell apoptosis by activating the MDM2-TP53 pathway
por: Zhanfeng, Niu, et al.
Publicado: (2016)

The genetic association study of TP53 polymorphisms in Saudi obese patients
por: Sabir, Jamal S.M., et al.
Publicado: (2019)

The Functional TP53 rs1042522 and MDM4 rs4245739 Genetic Variants Contribute to Non-Hodgkin Lymphoma Risk
por: Fan, Chuanbo, et al.
Publicado: (2014)

TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population
por: Li, Yanli, et al.
Publicado: (2013)

TP53-induced glycolysis and apoptosis regulator promotes proliferation and invasiveness of nasopharyngeal carcinoma cells
por: WONG, ELAINE YUE LING, et al.
Publicado: (2015)

Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients
por: Schmidt, Marjanka K, et al.
Publicado: (2009)

MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
por: Makii, Chinami, et al.
Publicado: (2016)

The cell cycle regulatory gene polymorphisms TP53 (rs1042522) and MDM2 (rs2279744) in lung cancer: a meta-analysis
por: Bulgakova, O., et al.
Publicado: (2020)

Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review
por: Yu, Meijia, et al.
Publicado: (2022)

Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection
por: Li, Jing, et al.
Publicado: (2016)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation
por: Tracz-Gaszewska, Zuzanna, et al.
Publicado: (2017)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors
por: Alimova, Irina, et al.
Publicado: (2022)

Epstein-Barr virus infection mediated TP53 and Bcl-2 expression in nasopharyngeal carcinoma pathogenesis
por: Vatte, Chittibabu, et al.
Publicado: (2021)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Association between TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk in a Chinese population
por: Fu, Wen, et al.
Publicado: (2017)

The important role of MDM2, RPL5, and TP53 in mycophenolic acid-induced cleft lip and palate
por: Lin, Yangyang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ob6i2rr8dhqqohom827u7q9a1i